InSitu Biologics is an innovative biotech company that specializes in the development of a multi-phase, prolonged-release drug delivery platform aimed at localized treatment for pain, cancer, and infection. Their flagship products, INSB200™ and INSB400™, leverage advanced drug delivery technologies to address significant unmet needs in pain management and cancer therapy. INSB200™ is designed for peri-operative pain management, utilizing a single-injection nerve block that releases the anesthetic ropivacaine over an extended period of more than 96 hours. This approach not only enhances pain control but also minimizes opioid consumption and reduces the risk of infection, thereby improving patient recovery times and discharge efficiency.

INSB400™, on the other hand, focuses on the localized delivery of cancer therapeutics, allowing for a precise elution rate of anti-cancer drugs over a predetermined duration. This targeted delivery system aims to mitigate the severe adverse effects commonly associated with systemic chemotherapy by ensuring that therapeutic agents are administered directly to the affected areas. Both products are currently in the investigational pre-clinical stage, with InSitu Biologics actively pursuing partnerships, such as their recent co-development agreement with the Mayo Clinic, to advance their technologies and bring these innovative solutions to market.

United States

InSitu Biologics is an emerging biotech company focused on development of a multi-phase prolonged release drug delivery platform for localized treatment of pain, cancer, and infection. We use disruptive technology to address unmet needs in the pain management and drug delivery markets.

InSitu Biologics

Company Details